9 completed, 4 recruiting, 3 terminated, 1 active not recruiting. 18 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 9, Recruiting 4, Terminated 3, Active not recruiting 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow von Hippel-Lindau Disease: new trials by email Literature Review of von Hippel-Lindau Disease trials Research Report on von Hippel-Lindau Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau Disease investigating the role of CAIX as target in VHL disease and in VHL-/- tumors. - VHL - Von Hippel-Lindau Syndrome | Phase 2 | Recruiting | IRCCS Ospedale San Raffaele | 38 | 2026-02-25 | 2026-03-09 |
| Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial Belzutifan - Von Hippel Lindau, Von Hippel Lindau Disease | Phase 2 | Recruiting | José Claudio Casali da Rocha | 100 | 2024-01-01 | 2025-09-11 |
| 68Ga-NY104 PET/CT in Von Hippel-Lindau Disease 68Ga-NY104 PET/CT Contrast-enhanced MRI of the brain and contrast-enhanced CT of abdomen and pelvis) 68Ga-NODAGA-LM3 PET/CT (exploratory) - Von Hippel-Lindau Disease | Phase 2 | Unknown | Peking Union Medical College Hospital | 19 | 2023-05-01 | 2023-05-11 |
| Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) Belzutifan - Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 355 | 2021-08-12 | 2026-11-03 |
| Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors 68-Gallium DOTATATE - VHL Pancreatic Neuroendocrine Tumors, Von Hippel-Lindau Disease | Phase 2 | Recruiting | National Cancer Institute (NCI) | 740 | 2020-06-02 | 2026-10-16 |
| A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) Belzutifan - VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation | Phase 2 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 50 | 2018-05-02 | 2026-04-13 |
| MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) MK-3795 - VHL Gene Mutation, VHL | Phase 2 | Completed | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 4 | 2017-04-24 | 2024-09-24 |
| A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Ranibizumab, E10030 - Von Hippel-Lindau Syndrome | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 3 | 2017-01-23 | 2021-11-01 |
| Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors 68Gallium DOTATATE, Radio-guided surgery - Neuroendocrine Tumors, Von Hippel-Lindau Syndrome | Phase 2 | Completed | National Cancer Institute (NCI) | 341 | 2013-10-18 | 2019-11-19 |
| TKI 258 in Von Hippel-Lindau Syndrome (VHL) Dovitinib - Von Hippel-Lindau Syndrome | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2012-11-01 | 2017-02-13 |
| Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome Laboratory Biomarker Analysis, Pazopanib Hydrochloride - Von Hippel-Lindau Syndrome | Phase 2 | Completed | M.D. Anderson Cancer Center | 32 | 2012-01-17 | 2025-05-02 |
| Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease Sunitinib - Von Hippel-Lindau Disease | Phase 2 | Completed | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 5 | 2010-03-01 | 2012-09-13 |
| Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome Sunitinib Malate - Von Hippel-Lindau Syndrome | Phase 1 / Phase 2 | Terminated | National Eye Institute (NEI) | 2 | 2008-05-01 | 2024-01-05 |
| Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy ranibizumab injection (0.5 mg) - Coats' Disease, Idiopathic Retinal Telangiectasia | Phase 1 / Phase 2 | Completed | Manhattan Eye, Ear & Throat Hospital | 18 | 2007-05-01 | 2012-10-25 |
| Metabolic Mapping to Measure Retinal Metabolism Feasibility Study - Imaging System - Macular Degeneration, Diabetic Retinopathy | Phase 2 | Completed | National Eye Institute (NEI) | 28 | 2006-09-29 | 2017-07-02 |
| Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow SU011248 - Von Hippel-Lindau Syndrome, Renal Cell Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2006-05-01 | 2024-06-27 |
| 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease 17 allylamino-17-demethoxygeldanamycin, 18 FDG (Fludeoxyglucose 18F), [15-O] H2O - Hippel-Lindau Disease, Kidney Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2004-07-01 | 2012-07-27 |
| Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 PTK787/ZK 222584 - Von Hippel-Lindau Disease, CNS Hemangioblastoma | Phase 2 | Completed | Novartis Pharmaceuticals | 11 | 2003-02-01 | 2017-03-06 |
Carcinoma, Renal Cell (4) · Hemangioblastoma (4) · Neuroectodermal Tumors, Primitive (2) · Neuroendocrine Tumors (2) · Paraganglioma (2) · Pheochromocytoma (2) · Adenoma, Islet Cell (1) · Central Nervous System Neoplasms (1) · Cysts (1) · Diabetic Retinopathy (1) · Kidney Neoplasms (1) · Macular Degeneration (1) · Multiple Endocrine Neoplasia Type 1 (1) · Myopia, Degenerative (1)
Abnormalities, Multiple (18) · Angiomatosis (18) · Cardiovascular Diseases (18) · Ciliopathies (18) · Congenital Abnormalities (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Genetic Diseases, Inborn (18) · Nervous System Diseases (18) · Neurocutaneous Syndromes (18) · Vascular Diseases (18) · Neoplasms by Histologic Type (9) · Neoplasms (8) · Neoplasms by Site (7) · Neoplasms, Glandular and Epithelial (6) · Adenocarcinoma (4)
Sunitinib (3) · belzutifan (3) · Ranibizumab (2) · gallium Ga 68 dotatate (2) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · E10030 aptamer (1) · Fluorodeoxyglucose F18 (1) · Oxygen-15 (1) · PT2385 (1) · pazopanib (1) · tanespimycin (1) · vatalanib (1)
M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · National Eye Institute (NEI) (3) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (1) · IRCCS Ospedale San Raffaele (1) · José Claudio Casali da Rocha (1) · Manhattan Eye, Ear & Throat Hospital (1) · Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1) · Peking Union Medical College Hospital (1)
United States (14) · France (3) · China (2) · Denmark (2) · Italy (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · Germany (1) · Hungary (1) · Israel (1) · Japan (1) · Netherlands (1)
Eric Jonasch, MD (2) · Naris Nilubol, M.D. (2) · Catherine Meyerle, MD (1) · Eric Jonasch (1) · Henry E Wiley, M.D. (1) · Lawrence A. Yannuzzi, MD (1) · Li Huo, MD (1) · William M Linehan, M.D. (1)
PMID 34783716, PMID 22105611, PMID 30236511, PMID 34549489, PMID 34818478, PMID 39284337, PMID 40228516, PMID 41124218
2023 (2), 2018 (1)